Payment overview · 2025
General Payments
$1,149.42
30 reported records · 9 companies
Healthcare provider profile · identity verified
Karen E Mcgibbon, MD
Allopathic & Osteopathic Physicians|Family Medicine · LANHAM, MD · NPI 1689780579
Verified facts
What the public records show
CMS Open Payments records show Karen E Mcgibbon, MD received $1,149.42 in general payments during 2025 across 30 reported records.
Lilly USA, LLC accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $356.41 | 31.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $332.41 | 28.9% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $253.46 | 22.1% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $77.61 | 6.8% | 3 | 2025 |
| Brainsway USA INC | Unresolved — no canonical attribution shown | $50.23 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.57 | 2.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.18 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.99 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.56 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,149.42 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $278.21 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $200.86 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $179.19 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $124.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $120.83 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $77.61 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.27 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.27 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $54.20 | 3 | 2025 |
Source payment records
|
|||||
| Deep TMS System Normalized: deep tms system |
Device | Brainsway USA INC | $50.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 140 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
92 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1054 | 335 |
| Amlodipine Besylate | Amlodipine Besylate | 542 | 171 |
| Losartan Potassium | Losartan Potassium | 535 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 125 |
| Lisinopril | Lisinopril | 402 | 128 |
| Omeprazole | Omeprazole | 389 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 364 | 128 |
| Simvastatin | Simvastatin | 342 | 100 |
| Sertraline Hcl | Sertraline Hcl | 298 | 87 |
| Metformin Hcl | Metformin Hcl | 267 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 78 |
| Gabapentin | Gabapentin | 221 | 78 |
| Montelukast Sodium | Montelukast Sodium | 205 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 64 |
| Allopurinol | Allopurinol | 169 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 63 |
| Ozempic | Semaglutide | 140 | 36 |
| Meloxicam | Meloxicam | 126 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 37 |
| Atenolol | Atenolol | 123 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 35 |
| Trazodone Hcl | Trazodone Hcl | 112 | 37 |
| Furosemide | Furosemide | 111 | 34 |
| Azelastine Hcl | Azelastine Hcl | 102 | 61 |
| Famotidine | Famotidine | 101 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 31 |
| Bupropion Xl | Bupropion Hcl | 99 | 28 |
| Methylprednisolone | Methylprednisolone | 95 | 84 |
| Fenofibrate | Fenofibrate | 94 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 34 |
| Synthroid | Levothyroxine Sodium | 92 | 25 |
| Metformin Hcl Er | Metformin Hcl | 85 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 27 |
| Carvedilol | Carvedilol | 82 | 26 |
| Potassium Chloride | Potassium Chloride | 76 | 20 |
| Eliquis | Apixaban | 74 | 23 |
| Ezetimibe | Ezetimibe | 73 | 22 |
| Glimepiride | Glimepiride | 73 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 24 |
| Trulicity | Dulaglutide | 71 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 23 |
| Mounjaro | Tirzepatide | 67 | 21 |
| Prednisone | Prednisone | 66 | 51 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 37 |
| Naproxen | Naproxen | 59 | 28 |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 20 |
| Buspirone Hcl | Buspirone Hcl | 55 | 22 |
| Alendronate Sodium | Alendronate Sodium | 54 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 19 |
| Valsartan | Valsartan | 51 | 17 |
| Labetalol Hcl | Labetalol Hcl | 48 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 17 |
| Ibuprofen | Ibuprofen | 44 | 14 |
| Glipizide | Glipizide | 42 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 15 |
| Alprazolam | Alprazolam | 39 | 20 |
| Finasteride | Finasteride | 39 | 12 |
| Valacyclovir | Valacyclovir Hcl | 39 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 17 |
| Donepezil Hcl | Donepezil Hcl | 38 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Ibu | Ibuprofen | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 19 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 28 |
| Ketoconazole | Ketoconazole | 32 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 12 |
| Tramadol Hcl | Tramadol Hcl | 28 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nystatin | Nystatin | 26 | 12 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Diazepam | Diazepam | 17 | 11 |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,149.42 · 30 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, Deep TMS System, Flexitouch Plus, KISUNLA, MOUNJARO, Nimbl, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error